Information Provided By: 
Fly News Breaks for July 12, 2017
DRRX
Jul 12, 2017 | 07:09 EDT
As noted earlier, Stifel upgraded Durect to Buy from Hold. Analyst Adam Walsh predicts that the stock will rise over the next 12-18 months. The analyst is optimistic about the outlook for a Phase 3 trial of the company's Posimir drug due out in Q4 and is pleased by the company's deal with Sandoz for U.S. rights to the drug. Walsh adds that Durect's '928 "appears (to be) a highly safe, potent, and active compound with broad therapeutic potential." Target to $3 from $1.25.
News For DRRX From the Last 2 Days
There are no results for your query DRRX
